Compare CVS Health Corp (CVS) vs Nutrien Ltd (NTR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
CVS Health Corp vs Nutrien Ltd — how do they compare? CVS Health Corp trades at $93.7 (market cap $122.36B), while Nutrien Ltd trades at $67.28 (market cap $31.60B). The key difference: CVS Health Corp is far larger — about 3.9× Nutrien Ltd's market cap, and Nutrien Ltd pays the higher dividend (3.32%). Which is the better fit depends on your goals.
| CVS | NTR | |
|---|---|---|
Market Cap | $122.36B | $31.60B |
Sector | Health | Basic Materials |
52-Week High | $110.60 | $83.94 |
52-Week Low | $65.51 | $53.64 |
Enterprise Value | $184.71B | $43.40B |
Dividend Yield | 2.78% | 3.32% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CVS Health trades at $95.70, down 0.54% on the day, with a bearish technical signal and key support at $95. The company reported strong Q2 2026 earnings, beating estimates with EPS of $2.58 versus $1.87 expected, and raised its full-year guidance. Revenue growth remains robust, reaching $402.07 billion in 2025, though net income margin compressed to 1.18%. Analyst sentiment is overwhelmingly positive with a consensus price target of $115.00.
The outlook for CVS is cautiously optimistic, driven by operational improvements in its Aetna segment and raised cash flow guidance. Investment opportunities include potential upside to the consensus target, but risks involve margin pressures, regulatory changes impacting pharmacy benefits in 2027, and high debt levels. The stock's current valuation at a P/E of 25.25 may limit near-term gains if earnings growth slows.
Nutrien Ltd. (NTR) trades at $64.42, down 3.51% over 24 hours, with a bearish technical signal. The stock shows mixed earnings, missing Q2 2026 EPS estimates but beating in Q1. Fundamentals include a P/E of 13.04, net income margin of 8.44%, and a dividend of $0.55 per share. Recent news highlights strong potash sales and cost management, though input cost pressures persist.
The outlook is cautiously optimistic, supported by analyst consensus of $76.67 price target and 60.61% buy ratings. Key opportunities include structural gas advantages and agricultural cycle recovery, while risks involve volatile fertilizer demand and margin compression from higher costs.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About CVS Health Corp
Following its acquisition of Aetna in late 2018, CVS Health now provides an even more integrated healthcare-services offering for its members. Legacy CVS combined both the largest pharmacy benefit manager, processing over 2 billion adjusted claims annually, and a sizable pharmacy operation, including nearly 10,000 retail pharmacy locations primarily in the U.S. Adding a managed-care organization with 24 million medical members gives the company a strong position in the insurance industry and should help CVS better control overall healthcare costs for its clients.
Read more on CVS →About Nutrien Ltd
Created in 2018 as a result of the merger between PotashCorp and Agrium, Nutrien is the world's largest fertilizer producer by capacity. Nutrien produces the three main crop nutrients--nitrogen, potash, and phosphate--although its main focus is potash, where it is the global leader in installed capacity with roughly 20% share. The company is also the largest agricultural retailer in the United States, selling fertilizers, crop chemicals, seeds, and services directly to farm customers through its brick-and-mortar stores and online platforms.
Read more on NTR →
